Effetto dell'interferone gamma come trattamento per l'immunosoppressione post-aggressiva nelle unità di terapia intensiva, uno studio bayesiano randomizzato controllato in doppio cieco rispetto al placebo (INFINITY)
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).
This immunological adaptation, initially implemented as a host defense mechanism to protect against an overwhelming systemic reaction, can, if prolonged, lead to multiple complications resulting in significant delayed morbidity and mortality. Diagnosis is based on the use of immuno-inflammatory biomarkers, the most widely studied of which is monocyte expression of major histocompatibility complex type II molecules (mHLA-DR).
We have recently confirmed that PAIS can affect all types of patients admitted to the intensive care unit, but mainly occurs in the most severe patients. We also showed that the occurrence of PAIS was strongly associated with the subsequent occurrence of secondary infection and excess mortality.
Currently, there is no treatment with proven efficacy for PAIS, but several drugs have been shown to restore leukocyte function in-vitro. Several teams have reported the use of immunostimulatory molecules in patients with treatment failure, with a good safety profile and encouraging results. We believe that earlier treatment of patients with proven PAIS could improve their clinical outcome.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Charles De ROQUETAILLADE, MD
- Numero di telefono: +33 01 49 95 55 68
- Email: charles.de-roquetaillade@aphp.fr
Backup dei contatti dello studio
- Nome: Benjamin CHOUSTERMAN, Professor
- Numero di telefono: +33 01 49 95 85 18
- Email: benjamin.chousterman@aphp.fr
Luoghi di studio
-
-
-
Limoges, Francia, 87000
- Reclutamento
- Dr Francois Bruno
-
Contatto:
- Bruno Francois, MD
- Numero di telefono: +33 05 55 05 88 41
- Email: bruno.françois@chu-limoges.fr
-
Nancy, Francia
- Reclutamento
- Pr Antoine Kimmoun
-
Contatto:
- Antoine Kimmoun, Professor
- Numero di telefono: +33 03 83 85 14 95
- Email: a.kimmoun@chru-nancy.fr
-
Paris, Francia
- Reclutamento
- Pr Dépret
-
Contatto:
- Pr Dépret François, Professor
- Numero di telefono: +33 01 42 49 95 70
- Email: francois.depret@aphp.fr
-
Paris, Francia, 75010
- Reclutamento
- Pr Benjamin Chousterman
-
Contatto:
- Chousterman Benjamin, Professor
- Numero di telefono: +33 0149958518
- Email: benjamin.chousterman@aphp.fr
-
Paris, Francia, 75013
- Reclutamento
- Pr Constantin Michel
-
Contatto:
- Michel Constantin, Professor
- Numero di telefono: +33 01 42 16 22 59
- Email: Jean-michel.constantin@aphp.fr
-
Paris, Francia
- Reclutamento
- Pr Megarbane
-
Contatto:
- Bruno Megarbane, Professor
- Numero di telefono: +33 01 49 95 84 42
- Email: Bruno.megarbane@aphp.fr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patient ≥ 18 years old
- SOFA score for first 24 hours post-admission ≥ 6
- Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded)
- mHLA-DR< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit
- Patient affiliated to a social security scheme
- Written informed consent from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible
Exclusion Criteria:
- Patient with estimated life expectancy of less than 3 months
- Patients with a predicted remaining stay in intensive care < 72 hours
- Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score < 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation
- Pregnant or breast-feeding women
- Contraindication of Imukin (hypersensitivity to interferon gamma-1b or known hypersensitivity to related products, such as another interferon)
- Patients on immunosuppressive therapy, including long-term corticosteroid therapy (>2.5mg/d prednisone equivalent)
- Patients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
- Patient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
- People under court protection and protected adults
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: interferon gamma-1b injection
Patients randomized to the experimental arm will receive : Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
|
|
Comparatore placebo: Placebo injection
Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
number of days alive without mechanical ventilation
Lasso di tempo: on Day 28 after drug administration
|
number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day |
on Day 28 after drug administration
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Evaluate the efficacy of IFNy in correcting PAIS-defining biological abnormalities (re-ascension of mHLA-DR above 8,000 AB/C) between patients treated with recombinant interferon gamma 1-b versus placebo
Lasso di tempo: Day 1 to Day 7 and at Day 28 post randomization
|
Evolution of mHLA-DR measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo. |
Day 1 to Day 7 and at Day 28 post randomization
|
|
Evaluate, depending on the randomization arm, the kinetics of plasma inflammatory parameters between patients treated with recombinant interferon gamma 1-b versus placebo
Lasso di tempo: Day 0, Day 3 and at Day 7 post randomization
|
Evolution of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at Day 0, Day 3 and Day 7, or at discharge from intensive care if it occurs before (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 0, Day 3 and at Day 7 post randomization
|
|
mortality at Day 28 and Day 90 after randomization
Lasso di tempo: Day 28 and Day 90 after randomization
|
Mortality rate at Day 28 and Day 90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 28 and Day 90 after randomization
|
|
incidence of nosocomial infections during intensive care unit stay
Lasso di tempo: from Day 0 to Day 28 (or the discharge from intensive care)
|
The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo |
from Day 0 to Day 28 (or the discharge from intensive care)
|
|
number of days alive whithout antibiotic
Lasso di tempo: Day 28 after drug administration
|
Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 28 after drug administration
|
|
length of stay in intensive care between patients
Lasso di tempo: from Day 0 to Day 28 (or the discharge from intensive care)
|
Number of days in intensive care between patients treated with recombinant interferon gamma 1-b versus placebo |
from Day 0 to Day 28 (or the discharge from intensive care)
|
|
- Compare organ failure score (SOFA) kinetics between patients treated with recombinant interferon gamma 1-b versus placebo
Lasso di tempo: From inclusion to Day 7
|
Kinetics of SOFA score assessed at inclusion and during the 7 days following inclusion between patients treated with recombinant interferon gamma 1-b versus placebo |
From inclusion to Day 7
|
|
Evaluate, depending on the randomization arm, the transcriptomic profile of circulating peripheral blood mononuclear cells count between patients treated with recombinant interferon gamma 1-b versus placebo
Lasso di tempo: Day 0, Day 3 and Day 7 after randomization
|
Evolution of the transcriptomic profile of circulating peripheral blood mononuclear cells (PBMCs) using scRNAseq analysis measured at Day 0, Day 3 and Day 7 or upon discharge from intensive care if this occurs earlier. |
Day 0, Day 3 and Day 7 after randomization
|
|
Evaluate, depending on the randomization arm the leucocyte count between patients treated with recombinant interferon gamma 1-b versus placebo
Lasso di tempo: Day 0 to Day 7 and at Day 28 post randomization
|
Evolution and kenetics of the leucocyte count measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 0 to Day 7 and at Day 28 post randomization
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Cattedra di studio: Benjamin Chousterman, Professor, APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Infezioni
- Sindrome da risposta infiammatoria sistemica
- Infiammazione
- Condizioni patologiche, segni e sintomi
- Sepsi
- Peptidi
- Aminoacidi, peptidi e proteine
- Proteine
- Fattori biologici
- Peptidi e proteine di segnalazione intercellulare
- Citochine
- Interferoni
- Linfokine
- Fattori attivanti macrofagi
- Interferone gamma
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- APHP220672
- 2023-506725-11-00 (Ctis)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .